Please login to the form below

Not currently logged in
Email:
Password:

Michael Cola resigns as president of Shire Specialty Pharmaceuticals

Leaves to "explore new career opportunities and challenges”

Michael Cola - ShireShire's Michael Cola is to resign as president of the company's specialty pharmaceuticals business.

“With the company in a position of tremendous strength it is time for me to explore new career opportunities and challenges,” he said. “It has been an honour to work with my colleagues at Shire.”

Cola had been with Shire for seven years, joining as executive VP and general manager for the company's global therapeutic business units.

He assumed the role of president of the specialty pharmaceuticals business in 2006.

His role will be taken over by the company's CEO Angus Russell while the search for a new president is carried out.

Russell said: “As president of the SP business, Mike was instrumental in helping Shire transform itself from a company dominated by a single product in one market to a leading global biopharmaceutical company with a diversified product portfolio.”

Prior to joining Shire, Cola held several executive positions at pharma companies, including Merck,  AstraZeneca and Safeguard Scientifics.

3rd April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Indigenus

A global healthcare communications network dedicated to helping clients grow their brands. Unstuck, with an entrepreneurial and nimble spirit....

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics